Anti-Human EGFR – DyLight® 755

Anti-Human EGFR – DyLight® 755

Product No.: E331

[product_table name="All Top" skus="E331"]

- -
- -
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
ERBB, ERBB1, mENA,Epidermal Growth Factor Receptor
IgG2b κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
Purified Recombinant Human EGFR (>98%)
Product Concentration
0.1 mg/ml
This DyLight<sup>®</sup> 755 conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 755 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone EGFR.1 recognizes the human EGFR.
EGFR is a 170 kD transmembrane glycoprotein that is part of the ErbB family of receptors within the protein kinase superfamily. EGFR is one of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR is essential for various processes including controlling cell growth and differentiation and ductal development of the mammary glands. Ligand binding induces dimerization and autophosphorylation. It consists of a glycosylated extracellular domain which binds to EGF and an intracellular domain with tyrosine-kinase activity necessary for signal transduction. TGFα, vaccinia virus growth factor, and related growth factors can also bind to and signal through EGFR. Abnormal EGFR signaling has been implicated in inflammatory diseases such as psoriasis, eczema and atherosclerosis. Alzheimer's disease is linked with poor signaling of the EGFR and other receptor tyrosine kinases. Furthermore, over-expression of the EGFR is linked with the growth of various tumors. EGFR has been identified as an oncogene, a gene which in certain circumstances can transform a cell into a tumor cell, which has led to the therapeutic development of anticancer EGFR inhibitors. EGFR is a well-established target for both mAbs and specific tyrosine kinase inhibitors.

Antigen Details

NCBI Gene Bank ID
Research Area
Cell Biology
Innate Immunity
Synaptic Biology

References & Citations

1. Berger, SM. et al. (1987) J. of Pathology 152:297
2. Downward, J. et al. (1984) Nature 311:483
3. Gullick, WJ. et al. (1985) EMBO J. 4:2869
4. Gullick, WJ. et al. (1986) Cancer Research 46:285
5. Gullick, WJ. et al. (1991) Br. Med. Bulletin 47:87
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.